Abstract 1694MO
Background
The effect of a cancer diagnosis is wide-ranging with potential negative impact on socioeconomic life such as high (in)direct treatment-related costs and income loss. These socioeconomic consequences differ per country, healthcare setting and patient population. Adolescents and young adults (AYAs), 18-39 years old at cancer diagnosis, are recognized as a distinct population within the oncology community with age-specific problems and needs. Insight into the socioeconomic consequences of cancer at this young age is of utmost importance to provide the best possible supportive care to this group. This study explores the socio-economic consequences among AYAs across 11 European countries.
Methods
This study presents a sub-analysis of the SEC-Study data, focusing on AYAs who were currently treated or treated before. Participants were included by hospitals of the Organization of European Cancer Institutes network and patient organizations in 11 countries (Belgium, Bulgaria, Cyprus, Denmark, Finland, France, Germany, Netherlands, Norway, Spain, Switzerland). Next to measuring financial distress through the Financial Index of Toxicity, our survey explored other socio-economic consequences like income loss, coping behaviour regarding treatment related expenses and access to financial services.
Results
316 AYA cancer patients participated (median age: 35 years), of which 38% had to permanently quit their job due to their cancer (range: 19% (France, Norway); 71% (Spain)) and 70% suffered from income loss (range: 53% (Bulgaria); 89% (Belgium)). AYAs coped by using their savings (43%), spending less on luxury goods/ leisure activities (37%), spending less on basic goods (29%), applying for financial assistance (26%), or borrowing money (20%), although differences exist between countries. Most AYAs (82%) were worried about their family’s financial situation and 58% stated it’s important to them to discuss the personal cost of treatment with their doctor.
Conclusions
This European study shows that many AYAs face serious socio-economic consequences, although differences exist between countries. Those AYA cancer patients at risk of impacted socio-economic outcomes require bespoke financial support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The project has been funded by the European Fair Pricing Network and the Organization of European Cancer Institutes.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1692MO - Is project Orbis successful? The Swiss perspective
Presenter: Matea Pavic
Session: Mini oral session - Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1693MO - The high burden of long-term and late health-related problems among adolescent and young adult cancer survivors: Results of the SURVAYA study
Presenter: Silvie Janssen
Session: Mini oral session - Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1695MO - Cancer care during armed conflict: Factors associated with adult patient transfer for treatment abroad during the war in Ukraine
Presenter: Inesa Huivaniuk
Session: Mini oral session - Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
Invited Discussant 1692MO, 1693MO, 1694MO and 1695MO
Presenter: James McKay
Session: Mini oral session - Policy and preventive strategies
Resources:
Slides
Webcast
1759MO - Clinical breast examination for early diagnosis of breast cancer: An Egyptian nationwide study
Presenter: Loay Kassem
Session: Mini oral session - Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1696MO - Partial orphan cancer drugs: FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending
Presenter: Daniel Michaeli
Session: Mini oral session - Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1697MO - Spending on and beneficiaries of orphan cancer drugs for ultra-rare, rare, and common diseases
Presenter: Julia Caroline Michaeli
Session: Mini oral session - Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
Invited Discussant 1759MO, 1696MO and 1697MO
Presenter: Tit Albreht
Session: Mini oral session - Policy and preventive strategies
Resources:
Slides
Webcast
1698MO - E-cigarette use among us ever-smoking cancer survivors and its implications on lung cancer screening
Presenter: Qian Wang
Session: Mini oral session - Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1699MO - Intervening factors for participation and non-participation in colorectal cancer screening in Spain
Presenter: Maria Luz Amador
Session: Mini oral session - Policy and preventive strategies
Resources:
Abstract
Slides
Webcast